Avery developed osteoporosis after taking Ozempic for about a year without a doctor's supervision. She originally sought the ...

Several local companies are developing technologies that they hope could replace a painful poke with something that feels more like having Velcro against your skin for a few minutes.

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Semaglutide — the active substance in Ozempic and Wegovy — may help reduce alcohol cravings in people with alcohol use ...

Six percent of Americans have used Ozempic, Wegovy and similar drugs. They’re unwitting experimental subjects.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

On the one hand, we see the rise of weight-loss drugs like Ozempic, hailed as a revolutionary aid for those who can afford it. Conversely, the body positivity movement encourages self-acceptance ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

By now, these are household names: Mounjaro. Wegovy. Zepbound… and yes, Ozempic. A Kaiser Family Foundation poll found that one in 8 American adults reported trying a GLP-1 medication.